Texas governor backs off mandatory Gardasil vaccination effort: AP

Share this article:
Texas’ Republican Gov. Rick Perry has backed away from his efforts to require pre-teen girls to be vaccinated against the cervical cancer-causing human papillomavirus (HPV) after the state legislature overturned his order. The February order would have made Texas the first US state to require that girls receive Merck’s Gardasil HPV vaccine so they can enroll in sixth grade, when most students are 11 or 12 years old. Social conservatives opposed the mandatory vaccination program, saying it would lead to sexual promiscuity. The Republican-majority Texas legislature passed a bill last month overturning the order by preventing the vaccination program for at least four years, the Associated Press reported. Perry said he would not veto the bill, meaning it will become law, according to the AP report. Perry said a veto was futile since the legislature would vote to override it. The governor blasted the legislature for its decision. “They have sent me a bill that ensures three-quarters of our young women will be susceptible to a virus that not only kills hundreds each year, but causes great discomfort and harm to thousands more,” Perry said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...